These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 16905789)

  • 1. Metabolic and skeletal complications of HIV infection: the price of success.
    Morse CG; Kovacs JA
    JAMA; 2006 Aug; 296(7):844-54. PubMed ID: 16905789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic and cardiovascular complications of highly active antiretroviral therapy for HIV infection.
    Barbaro G
    Curr HIV Res; 2006 Jan; 4(1):79-85. PubMed ID: 16454713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reviewing the cardiovascular complications of HIV infection after the introduction of highly active antiretroviral therapy.
    Barbaro G
    Curr Drug Targets Cardiovasc Haematol Disord; 2005 Aug; 5(4):337-43. PubMed ID: 16101566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular risk and body-fat abnormalities in HIV-infected adults.
    Grinspoon S; Carr A
    N Engl J Med; 2005 Jan; 352(1):48-62. PubMed ID: 15635112
    [No Abstract]   [Full Text] [Related]  

  • 5. Highly active antiretroviral therapy-associated metabolic syndrome and cardiovascular risk.
    Barbaro G; Barbarini G
    Chemotherapy; 2006; 52(4):161-5. PubMed ID: 16675900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [HIV infection: emerging issues and new challenges].
    Calza L; Manfredi R; Chiodo F
    Recenti Prog Med; 2006 Dec; 97(12):771-80. PubMed ID: 17252736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia.
    Samaras K; Wand H; Law M; Emery S; Cooper D; Carr A
    Diabetes Care; 2007 Jan; 30(1):113-9. PubMed ID: 17192343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV lipodystrophy and its metabolic consequences: implications for clinical practice.
    Wierzbicki AS; Purdon SD; Hardman TC; Kulasegaram R; Peters BS
    Curr Med Res Opin; 2008 Mar; 24(3):609-24. PubMed ID: 18208641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Highly active antiretroviral therapy and cardiovascular complications in HIV-infected patients.
    Barbaro G; Klatt EC
    Curr Pharm Des; 2003; 9(18):1475-81. PubMed ID: 12769727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of premature atherosclerosis and ischemic heart disease associated with HIV infection and antiretroviral therapy.
    Calza L; Manfredi R; Pocaterra D; Chiodo F
    J Infect; 2008 Jul; 57(1):16-32. PubMed ID: 18358535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipodystrophy, insulin resistance, diabetes mellitus, dyslipidemia, and cardiovascular disease in human immunodeficiency virus infection.
    Tanwani LK; Mokshagundam SL
    South Med J; 2003 Feb; 96(2):180-8; quiz 189. PubMed ID: 12630645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Lipodystrophy syndrome in HIV-infected patients. Clinical and diagnostic features].
    Streinu-Cercel A; Ion DA; Chivu LI; Chivu RD
    Rev Med Chir Soc Med Nat Iasi; 2006; 110(3):521-5. PubMed ID: 17571539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients.
    Calza L; Manfredi R; Chiodo F
    J Antimicrob Chemother; 2004 Jan; 53(1):10-4. PubMed ID: 14645323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The basis and management of metabolic abnormalities associated with cardiovascular risk in human immunodeficiency virus infection and its treatment.
    Crook M
    Ann Clin Biochem; 2007 May; 44(Pt 3):219-31. PubMed ID: 17456292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Metabolic abnormalities, lipodystrophy and cardiovascular risk in HIV-infected patients].
    Leclercq P; Blanc M
    Rev Prat; 2006 May; 56(9):987-94. PubMed ID: 16775979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipodystrophy and metabolic abnormalities in Slovenian HIV-infected patients.
    Tomazic J; Silic A; Karner P; Vidmar L; Maticic M; Poljak M; Ihan A; Janez A
    Wien Klin Wochenschr; 2004 Nov; 116(21-22):755-9. PubMed ID: 15628647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular considerations in patients treated with HIV protease inhibitors.
    Colagreco JP
    J Assoc Nurses AIDS Care; 2004; 15(1):30-41. PubMed ID: 14983559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The metabolic syndrome, an epidemic among HIV-infected patients on HAART.
    Jevtović DJ; Dragović G; Salemović D; Ranin J; Djurković-Djaković O
    Biomed Pharmacother; 2009 Jun; 63(5):337-42. PubMed ID: 18996676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of highly active antiretroviral therapy associated metabolic abnormalities and lipodystrophy in HIV infected patients.
    Feleke Y; Fekade D; Mezegebu Y
    Ethiop Med J; 2012 Jul; 50(3):221-30. PubMed ID: 23409405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Side effects of antiretroviral therapy].
    Teodor A; Teodor D; Luca V
    Rev Med Chir Soc Med Nat Iasi; 2004; 108(1):23-6. PubMed ID: 15688751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.